Compare ONT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONT | ABUS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.6M | 839.5M |
| IPO Year | 2020 | 2008 |
| Metric | ONT | ABUS |
|---|---|---|
| Price | $15.91 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 846.6K | ★ 2.9M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | ★ $830,538,000.00 | $14,083,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $239.71 |
| P/E Ratio | ★ N/A | $6.19 |
| Revenue Growth | 19.26 | ★ 128.21 |
| 52 Week Low | $12.68 | $3.50 |
| 52 Week High | $23.32 | $5.45 |
| Indicator | ONT | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 66.76 |
| Support Level | $12.68 | $4.15 |
| Resistance Level | $22.67 | $5.38 |
| Average True Range (ATR) | 1.46 | 0.18 |
| MACD | -0.22 | 0.07 |
| Stochastic Oscillator | 50.93 | 74.76 |
Onterris Inc is an environmental solutions company. The company provides environmental solutions to organizations addressing regulatory, operational, and environmental challenges. Its services include the application of scientific, engineering, and data-driven approaches to support risk management, compliance, and environmental protection, including air, water, and soil.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.